ATE273716T1 - Verfahren zur herstellung eines arzneimittelkomplexes - Google Patents

Verfahren zur herstellung eines arzneimittelkomplexes

Info

Publication number
ATE273716T1
ATE273716T1 AT97924326T AT97924326T ATE273716T1 AT E273716 T1 ATE273716 T1 AT E273716T1 AT 97924326 T AT97924326 T AT 97924326T AT 97924326 T AT97924326 T AT 97924326T AT E273716 T1 ATE273716 T1 AT E273716T1
Authority
AT
Austria
Prior art keywords
spacer
drug compound
bound
carboxyl groups
polysaccharide derivative
Prior art date
Application number
AT97924326T
Other languages
English (en)
Inventor
Kazuhiro Inoue
Hiroshi Susaki
Masahiro Ikeda
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of ATE273716T1 publication Critical patent/ATE273716T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT97924326T 1996-06-06 1997-06-05 Verfahren zur herstellung eines arzneimittelkomplexes ATE273716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14452296 1996-06-06
PCT/JP1997/001915 WO1997046261A1 (en) 1996-06-06 1997-06-05 Process for producing drug complexes

Publications (1)

Publication Number Publication Date
ATE273716T1 true ATE273716T1 (de) 2004-09-15

Family

ID=15364300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97924326T ATE273716T1 (de) 1996-06-06 1997-06-05 Verfahren zur herstellung eines arzneimittelkomplexes

Country Status (16)

Country Link
US (1) US6291671B1 (de)
EP (1) EP0955064B1 (de)
JP (1) JP4137184B2 (de)
CN (1) CN1227034C (de)
AT (1) ATE273716T1 (de)
AU (1) AU723442B2 (de)
CA (1) CA2257233A1 (de)
DE (1) DE69730352T2 (de)
DK (1) DK0955064T3 (de)
EA (1) EA001897B1 (de)
ES (1) ES2229355T3 (de)
ID (1) ID17243A (de)
NO (1) NO323626B1 (de)
PT (1) PT955064E (de)
TW (1) TW409058B (de)
WO (1) WO1997046261A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1250293C (zh) * 1998-05-22 2006-04-12 第一制药株式会社 药物复合物
MXPA02012791A (es) * 2000-06-29 2003-12-11 Daiichi Seiyaku Co Compuestos dds y metodo para prepararlo.
WO2002090390A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
EP1877447B1 (de) 2005-05-05 2016-12-21 Sensient Flavors Inc. Herstellung von betaglukanen und mannanen
RU2429018C2 (ru) 2005-07-06 2011-09-20 Сейкагаку Корпорейшн Гель, полученный из фотосшитой гиалуроновой кислоты с введенным лекарственным средством
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP3858385A3 (de) 2010-05-25 2021-10-27 Syndevrx, Inc. Polymer-konjugierte metap2-hemmer und therapeutische verfahren zu ihrer verwendung
HUE039000T2 (hu) 2012-10-11 2018-12-28 Daiichi Sankyo Co Ltd Antitest-gyógyszer konjugát
EP2910573B1 (de) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat
BR112015025892A2 (pt) 2013-04-10 2017-07-25 Syndevrx Inc inibidores de metap2 e métodos para tratar obesidade
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CA2933666C (en) 2013-12-25 2021-08-03 Sapporo Medical University Anti-trop2 antibody-drug conjugate
DK3466976T3 (da) 2014-01-31 2021-12-13 Daiichi Sankyo Co Ltd Anti-her2-antistof-lægemiddelkonjugat
KR102624244B1 (ko) 2014-04-10 2024-01-11 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
JP2019501898A (ja) 2015-12-10 2019-01-24 シンデブルックス,インコーポレイティド フマギロール誘導体およびその多形体
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
WO2018135501A1 (ja) 2017-01-17 2018-07-26 第一三共株式会社 抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
KR102630307B1 (ko) 2017-08-31 2024-01-29 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
CA3073924C (en) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
CA3100608A1 (en) 2018-05-18 2019-11-21 Daiichi Sankyo Co., Ltd. Anti-muc1 antibody-drug conjugate
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス,インコーポレイティド MetAP2阻害剤のバイオマーカーとその応用
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
EP3996749A1 (de) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptidkonjugate von auf mikrotubuli abzielenden mitteln als therapeutische wirkstoffe
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3152319C2 (de) * 1980-09-03 1986-05-07 Kyosei Pharmaceutical Co., Ltd., Hokkaido Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera
JPS5746920A (en) * 1980-09-03 1982-03-17 Kyosei Seiyaku Kk Drug for digestive tract
JPS59220197A (ja) * 1983-05-30 1984-12-11 Snow Brand Milk Prod Co Ltd 新規な含窒素多糖体およびその製造方法
JP2604930B2 (ja) 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
DE69225542T2 (de) 1991-02-21 1998-09-10 Drug Delivery System Inst Ltd Carboxymethylmannoglukan und derivate davon
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
WO1994019376A1 (en) 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts

Also Published As

Publication number Publication date
AU723442B2 (en) 2000-08-24
CA2257233A1 (en) 1997-12-11
EP0955064A1 (de) 1999-11-10
ES2229355T3 (es) 2005-04-16
CN1227034C (zh) 2005-11-16
DE69730352T2 (de) 2005-09-08
EP0955064B1 (de) 2004-08-18
NO985667L (no) 1999-02-04
WO1997046261A1 (en) 1997-12-11
ID17243A (id) 1997-12-11
NO985667D0 (no) 1998-12-04
DE69730352D1 (de) 2004-09-23
DK0955064T3 (da) 2004-12-06
EA199900002A1 (ru) 1999-08-26
CN1227500A (zh) 1999-09-01
AU2978897A (en) 1998-01-05
EP0955064A4 (de) 2000-12-06
US6291671B1 (en) 2001-09-18
NO323626B1 (no) 2007-06-18
PT955064E (pt) 2004-10-29
EA001897B1 (ru) 2001-10-22
TW409058B (en) 2000-10-21
JP4137184B2 (ja) 2008-08-20

Similar Documents

Publication Publication Date Title
DE69730352D1 (de) Verfahren zur herstellung eines arzneimittelkomplexes
DE69530242D1 (de) Verfahren zur Herstellung von Glutaminsäure durch Fermentation
AU6614594A (en) Method of producing sustained-release preparation
ATE121088T1 (de) Verfahren zur herstellung von imidazo(4,5- c>chinolin-4-aminen.
ATE121414T1 (de) Verfahren zur herstellung von erythromcin a-oxim oder eines salzes davon.
DE60031208D1 (de) Verfahren zur Herstellung von Mikroperlen die fettlösliche Substanzen enthalten
CA2399187A1 (en) Kahalalide compounds
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
ATA342186A (de) Verfahren zur herstellung eines organischen carbonsaeureanhydrids
ATE205498T1 (de) Verfahren zur herstellung von kaliumclavulanat
DE69520368D1 (de) Verfahren zur herstellung von 5-hydroxymethyl-thiazole
DE69319428D1 (de) Verfahren zur herstellung von vancomycin
ATE384067T1 (de) Verfahren zur herstellung von 3-cephemderivaten
ATE189220T1 (de) Verfahren zur herstellung von 7-(3-amino- sowie 3-aminomethyl-1-pyrrolidinyl)-3-chinolon- carbonsäuren sowie -naphthyridoncarbonsäuren
RU93004665A (ru) Микробиологический способ гидроксилирования азот-гетероциклических-карбоновых кислот
DE3751261D1 (de) Verfahren zur Herstellung eines Kohlensäureesters.
DE68925951D1 (de) Chemisches Verfahren zur Herstellung des Antibiotikums L 17392 (Deglukoteicoplanin) und dessen Salze
DE3765370D1 (de) Verfahren zur herstellung eines o-naphtochinondiazidsulfonsaeureesters.
PT83837A (de) Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
ATE128456T1 (de) Verfahren zur herstellung eines alpha-amino- alkohols.
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
ATE222887T1 (de) Verfahren zur herstellung von inorganischen salzen von optisch aktiven phenylglycin-derivaten
EP0226132A3 (de) Dipeptide mit C-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
DE58905083D1 (de) Verfahren zur herstellung von thiophenderivaten sowie dihydrothiophen-1-oxide.
DE69002568D1 (de) Verfahren zur herstellung von optisch aktiven 2-arylpropionsaeuren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0955064

Country of ref document: EP

REN Ceased due to non-payment of the annual fee